[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:conn-syndrome":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":34,"states":35},"Conn Syndrome",4,[7,15,22,28],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT05030545","Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study",[11],"Phase 4","RECRUITING","2026-08-26T02:17:42.501124Z","2026-05-05T02:43:28.643757Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT07007793","A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism",[19],"Phase 3","2026-08-26T02:15:27.567165Z","2026-05-05T02:35:31.716980Z",{"nct_id":23,"title":24,"phases":25,"status":12,"updated_at":26,"content_modified":27},"NCT03374215","Clinical and Molecular Characteristics of Primary Aldosteronism in Blacks",[],"2026-08-26T02:14:59.425132Z","2026-05-13T02:55:06.123506Z",{"nct_id":29,"title":30,"phases":31,"status":12,"updated_at":32,"content_modified":33},"NCT04278404","Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",[],"2026-08-26T02:19:13.549512Z","2026-05-13T02:55:06.246558Z",[],[36,40],{"state":37,"count":38,"slug":39},"Maryland",3,"maryland",{"state":41,"count":38,"slug":42},"Massachusetts","massachusetts"]